Literature DB >> 7731022

Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy]adenine.

H T Serafinowska1, R J Ashton, S Bailey, M R Harnden, S M Jackson, D Sutton.   

Abstract

A number of esters and amides of the anti-HIV nucleotide analogue 9-[2-(phosphonomethoxy)-ethoxy]adenine (1) have been synthesized as potential prodrugs and evaluated for oral bioavailability in mice. Dialkyl esters 17-20 were prepared via a Mitsunobu coupling of alcohols 8-11 with 9-hydroxypurine 12 whereas (acyloxy)alkyl esters 25-33 and bis-[(alkoxycarbonyl)methyl] and bis(amidomethyl) esters 34-39 were obtained by reaction of 1 with a suitable alkylating agent. Phosphonodichloridate chemistry was employed for the preparation of dialkyl and diaryl esters 42-65, and bis(phosphonoamidates) 66 and 67. Following oral administration to mice, most of the dialkyl esters 17-20 were well-absorbed and then converted to the corresponding monoesters, but minimal further metabolism to 1 occurred. Bis[(pivaloyloxy)methyl] ester 25 displayed an oral bioavailability of 30% that was 15-fold higher than the bioavailability observed after dosing of 1. Methyl substitution at the alpha carbon of the bis[(pivaloyloxy)methyl] ester 25 (33) increased the oral bioavailability of 1 to 74%. Some of the diaryl esters also showed improved absorption properties in comparison with that of 1. In particular, the crystalline hydrochloride salt of diphenyl ester 55 was well-absorbed and efficiently converted to the parent compound with an oral bioavailability of 50%. On the basis of these results as well as the physicochemical properties of the prodrugs and their stability in mouse duodenal contents, the hydrochloride salt of diphenyl ester 55 was identified as the preferred prodrug of 1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731022     DOI: 10.1021/jm00008a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.

Authors:  James R Beadle; Kathy A Aldern; Xing-Quan Zhang; Nadejda Valiaeva; Karl Y Hostetler; Robert T Schooley
Journal:  Antiviral Res       Date:  2019-09-21       Impact factor: 5.970

Review 2.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

Review 3.  Phosphonate prodrugs: an overview and recent advances.

Authors:  Kenneth M Heidel; Cynthia S Dowd
Journal:  Future Med Chem       Date:  2019-07       Impact factor: 3.808

Review 4.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

5.  Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis, Stability, and Antiviral Activity.

Authors:  Kyle E Giesler; Jose Marengo; Dennis C Liotta
Journal:  J Med Chem       Date:  2016-07-22       Impact factor: 7.446

6.  Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand.

Authors:  Benjamin J Foust; Michael M Poe; Nicholas A Lentini; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  ACS Med Chem Lett       Date:  2017-08-09       Impact factor: 4.345

7.  Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs.

Authors:  J P Shaw; C M Sueoko; R Oliyai; W A Lee; M N Arimilli; C U Kim; K C Cundy
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

8.  Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.

Authors:  Andreas Brunschweiger; Jamshed Iqbal; Frank Umbach; Anja B Scheiff; Mercedes N Munkonda; Jean Sévigny; Aileen F Knowles; Christa E Müller
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

9.  Novel heteroaryl phosphonicdiamides PTPs inhibitors as anti-hyperglycemic agents.

Authors:  Kuruva Chandra Sekhar; Rasheed Syed; Madhava Golla; Jyothi Kumar M V; Nanda Kumar Yellapu; Appa Rao Chippada; Naga Raju Chamarthi
Journal:  Daru       Date:  2014-12-27       Impact factor: 3.117

10.  New prodrugs of Adefovir and Cidofovir.

Authors:  Tomáš Tichý; Graciela Andrei; Martin Dračínský; Antonín Holý; Jan Balzarini; Robert Snoeck; Marcela Krečmerová
Journal:  Bioorg Med Chem       Date:  2011-04-22       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.